FNCHQ · Finch Therapeutics Group, Inc.
$10.35
+0.00 (+0.00%)
At close · Sep 3
Going-concern doubt
— flagged Aug 13, 2024
Substantial doubt about the company's ability to continue as a going concern.
“due to the consideration of certain qualitative factors, including the Company's recurring losses from operations incurred since inception, the expectation of continuing operating losses for the foreseeable future, and uncertainty around its ability to successfully realize the full value of its intellectual property estate and other assets, the Company has concluded that there is substantial doubt regarding the Company's ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2024
Market Cap
$16.62M
Shares
1.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$10.35
Open$10.35
Day$10.35–10.35
52W close$6.21–14.56
Avg vol 30d2K
Short int385 · 0.0% float · 1.0d
Short vol94%
Last earningsMay 16, 2022
DataJun 2023–Sep 2026
Filing10-Q · Aug 13
Raw chart and full-history price indicators begin at the captured split on Jun 12, 2023; bars on opposite sides are not compared.
Up next
filed Aug 13, 2024
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$14.17M
Trailing 12 months
Revenue growth YoY
-87.6%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.1%
Year over year · more shares
Price change (1Y)
-20.4%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.47
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−10%
below
Price vs 50-day avg
+11%
above
RSI (14)
60
neutral
MACD trend
Negative
52-week position
50%
mid-range
Volume (OBV)
Bullish div.
accumulating
Momentum
relative strength
1-month return
−3%
trailing
6-month return
−23%
trailing
YTD return
−23%
this year
Relative strength
−40%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -1.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Squeeze score
24
low risk · 0–100
Fundamentals
Revenue growth
−88%
Y/Y
EPS growth
+35%
Y/Y
Free cash flow
$-31.5M
Balance sheet
$56.0M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−57%
past year
ATR
2.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−10%
Bearish
Price vs 50-day avg
+11%
Bullish
RSI (14)
60
Neutral
MACD trend
Negative
Bearish
52-week position
50%
Neutral
Volume (OBV)
Bullish div.
Bullish
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $9 › 200d $12 — 200d above 50d
Institutional flow
Distributing
-92% holders QoQ
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
0.02% of float · ▼ -1.8% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
1 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
Range low $6
Now $10 · 50%
Range high $15
vs 200-day avg -10%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FNCHQ
this stock
Finch Therapeutics Group, Inc.
|
$16.62M | -23.3% | -87.6% | — | 0.0% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$140.51B | +23.1% | +46.2% | 32.3 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.84B | +9.3% | +20.8% | 20.9 | 2.3% |
|
ARGX
Argenx SE
|
$65.63B | +25.3% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.96B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
Raw-price comparisons begin at the captured split on Jun 12, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FNCHQ | +1.5% | -2.8% | -23.3% | +1.5% | -23.3% |
| SPY | +0.3% | +0.6% | +16.7% | +0.8% | +13.4% |
| vs SPY | +1.2% | -3.4% | -40.1% | +0.7% | -36.6% |